UNIVERSAL ANTI-CD22 CHIMERIC ANTIGEN RECEPTOR ENGINEERED IMMUNE CELLS

The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CA...

Full description

Saved in:
Bibliographic Details
Main Authors DERRIEN, MURIELLE, SMITH, JULIANNE, DUCHATEAU, PHILIPPE
Format Patent
LanguageEnglish
French
Published 04.10.2018
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers. La présente invention concerne une cellule immunitaire modifiée dotée de nouveaux Récepteurs Antigéniques Chimériques anti-CD22 (RAC CD22) avec une délétion dans le gène TRAC qui est capable de rediriger ladite spécificité et réactivité de cellule immunitaire vers des cellules tumorales sélectionnées. Les cellules immunitaires modifiées dotées de ces RAC sont particulièrement appropriées pour traiter en particulier les cancers exprimant CD22 réfractaires récidives.
Bibliography:Application Number: CA20183058268